Search results for "thrombin"

showing 10 items of 201 documents

Increased risk for venous thrombosis in carriers of the prothrombin G→A20210 gene variant

1998

A mutation in the prothrombin gene (G--A20210) has been associated with higher plasma prothrombin levels and an increased tendency for venous thrombosis.To determine whether the prothrombin A20210 allele is independently associated with the occurrence of venous thrombosis.Case-control study.Two thrombosis centers in southern Italy.281 consecutive patients with venous thrombosis confirmed by objective tests and 850 controls.Medical history was collected on standardized questionnaires. The presence of prothrombin G--A2020 and factor V Leiden mutations was determined by polymerase chain reaction. The presence of anticoagulant factors and prothrombin activity was determined by tests of function…

AdultMaleHeterozygotePathologymedicine.medical_specialtyAdolescentStatistics as TopicGastroenterologyRisk FactorsSurveys and Questionnaireshemic and lymphatic diseasesInternal medicineBlood plasmaInternal MedicinemedicineFactor V LeidenHumansPoint MutationRisk factorChildVeinAllelesAgedAged 80 and overbusiness.industryVascular diseaseFactor VGeneral MedicineMiddle AgedThrombophlebitismedicine.diseaseThrombosisPulmonary embolismVenous thrombosismedicine.anatomical_structureCase-Control StudiesChild PreschoolMutationFemaleProthrombinbusinesscirculatory and respiratory physiology
researchProduct

Thrombosis in inherited factor VII deficiency

2003

Thrombosis in congenital factor (F) VII deficiency was investigated through extensive phenotypic and molecular-genetic studies. Patients with a history of thrombosis among 514 entries in the FVII Deficiency Study Group database were evaluated. Thrombotic events were arterial in one case, disseminated intravascular coagulation in another and venous in seven. Gene mutations were characterized in eight patients: three were homozygous, three compound heterozygous and two heterozygous. FXa and IIa generation assays were consistent with the genetic lesions. One patient was heterozygous for the FV Leiden and one for the FIIG20210A mutation. In seven patients, surgical interventions and/or replacem…

AdultMaleHeterozygotemedicine.medical_specialtyPathologyTime FactorsAdolescentFactor VII DeficiencyGene mutationCompound heterozygosityThrombophiliaGastroenterologyInternal medicinemedicineHumansThrombophiliaAgedVenous ThrombosisDisseminated intravascular coagulationbiologybusiness.industryHomozygoteFactor VFactor VThrombosisHematologyCongenital FVII deficiency; Replacement therapy; Surgery; Thrombophilia; Thrombosis;Disseminated Intravascular CoagulationMiddle Agedmedicine.diseaseThrombosisZygosityVenous thrombosisPhenotypeDatabases as TopicFactor XaMutationbiology.proteinFemaleProthrombinbusinessJournal of Thrombosis and Haemostasis
researchProduct

Mutation screening for the prothrombin variant G20210A by melting point analysis with the Light Cycler system: atypical results, detection of the var…

2005

In the differential diagnosis of thrombophilic disorders genotyping of prothrombin and factor V are nowadays performed as a routine analysis. In the following we describe the unusual results of the mutation screening using melting point analysis for two patients and the consecutive detection of the mutation C20209T by sequencing the corresponding gene fragments. The molecular result is discussed with special respect to the medical history, ethnic background and clinical findings of both patients.

AdultMaleHot TemperatureDNA Mutational AnalysisClinical BiochemistryBiologyNucleic Acid DenaturationThrombophiliaPolymerase Chain Reactionlaw.inventionlawmedicineHumansPoint MutationThrombophiliaMedical historyGenotypingPolymerase chain reactionGeneticsPoint mutationBiochemistry (medical)Factor VSequence Analysis DNAHematologyGeneral Medicinemedicine.diseaseMutation (genetic algorithm)biology.proteinFemaleProthrombinDifferential diagnosisClinical and Laboratory Haematology
researchProduct

Myocardial infarction marker levels are influenced by prothrombin and tumor necrosis factor-α gene polymorphisms in young patients.

2012

Polymorphisms of genes encoding key factors for the control and activation of inflammatory response and coagulation cascade regulation may play a role in genetic susceptibility to acute myocardial infarction (AMI). This study sought to analyze the effect of TNF - 308G/A and pro-thrombin (FII) 20210G/A polymorphisms on the laboratory parameters of young patients affected by AMI. Results indicated that TNF - 308A positive genotype frequencies were increased in these patients and that a genetically determined higher production of TNF-alpha is associated in young subjects to a more severe cardiac damage as depicted by higher levels of troponin, Creatine kinase-MB Isoenzyme (mCK-MB) and a signif…

AdultMalePro-thrombinGenotypeImmunologyMyocardial InfarctionSNPSingle-nucleotide polymorphismAcute myocardial infarctionPolymorphism Single NucleotideBiochemistryYoung AdultGene FrequencyGenotypeTroponin IGenetic predispositionCreatine Kinase MB FormHumansImmunology and AllergyMedicineGenetic Predisposition to DiseaseMolecular BiologyAllele frequencyInflammationbiologyTumor Necrosis Factor-alphabusiness.industryAge FactorsFibrinogenHematologyMiddle AgedTroponinTumor necrosis factor-a.TroponinGenotype frequencyImmunologyHaematochemical parameterbiology.proteinProthrombinCreatine kinasebusinessBiomarkers
researchProduct

Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study

2017

Background and aims: Patients on parenteral nutrition for short bowel syndrome (SBS) have a high risk of thrombotic complications and are often treated with parenteral anticoagulation. Direct oral anticoagulants are absorbed proximally in the digestive tract and may represent alternative regimens in selected SBS patients. In our pilot study, we provided pharmacokinetics parameters of dabigatran etexilate and rivaroxaban in this setting and compared peak (Cmax), trough (Ctrough) concentrations, and areas-under-the-concentration-time-curve (AUC(0) (-) (t)) to reference values retrieved from phase I-III studies. Methods: We enrolled 6 adults with a remaining small bowel length <= 200 cm, norma…

AdultMaleShort Bowel SyndromeParenteral Nutritionmedicine.medical_specialtyCmax030204 cardiovascular system & hematologyGastroenterologyAntithrombinsDabigatran03 medical and health sciences0302 clinical medicineRivaroxabanPharmacokineticsInternal medicinemedicineHumans030212 general & internal medicineDosingAgedRivaroxabanbusiness.industryHematologyMiddle AgedShort bowel syndromemedicine.diseaseCrossover studyDabigatranParenteral nutritionAnesthesiaFemalebusinessmedicine.drugThrombosis Research
researchProduct

Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behcet's disease and deep vein thrombosis

2004

OBJECTIVE: To evaluate the frequency and type of vascular lesions and to study the association of factor V gene G1691A (Leiden) and prothrombin gene G20210A polymorphisms with venous thrombosis in Italian patients with Behçet's disease (BD). METHODS: Included were 118 consecutive Italian BD patients followed over a 3-year period (1997-1999) who satisfied the International Study Group criteria for BD. The control group consisted of 132 healthy Italian blood donors. All BD patients and controls were genotyped by polymerase chain reaction and allele-specific restriction enzyme techniques for factor V Leiden and prothrombin gene G20210A polymorphisms. RESULTS: Vascular lesions were observed in …

AdultMaleVenous ThrombosisFactor V Leiden mutation Prothrombin G20210A mutationAdolescentGenotypeBehcet SyndromeFactor VMiddle AgedBehc ̧et’s disease; Deep vein thrombosis; Factor V Leiden mutation Prothrombin G20210A mutationAdolescent; Adult; Behcet Syndrome; Factor V; Female; Gene Frequency; Genotype; Humans; Italy; Male; Middle Aged; Prothrombin; Risk Factors; Venous Thrombosis; Point MutationGene FrequencyItalyDeep vein thrombosiRisk FactorsFactor V Leiden mutationHumansPoint MutationFemaleProthrombinProthrombin G20210A mutationBehcet’s disease
researchProduct

Prothrombotic State Induced by Middle-Distance Endurance Exercise in Middle-Aged Athletes

2018

AbstractSince the impact of possible prothrombotic factors on blood coagulation resulting from exercise remains elusive, this study investigated the acute effects of middle-distance endurance running on blood coagulation parameters in middle-aged athletes. The study population consisted of 33 male endurance runners who were engaged in a 21.1 km run under competitive conditions. Blood samples were collected before the run, immediately after the run, and 3 hours after run completion. Samples were assessed for activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen, D-dimer, factor VIII (FVIII), von Willebrand factor antigen (VWF:Ag), endogenous thrombin potential (area…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyphysical activity030204 cardiovascular system & hematologyFibrinogenRunningblood coagulation03 medical and health sciences0302 clinical medicineVon Willebrand factorEndurance traininghemic and lymphatic diseasesInternal medicineABO blood group systemvon Willebrand FactormedicineHumansExerciseblood coagulation; hemostasis; physical activity; thrombin generation; Adult; Blood Coagulation; Exercise; Factor VIII; Fibrinogen; Humans; Male; Middle Aged; Partial Thromboplastin Time; Physical Endurance; Running; Thrombin; Thrombosis; von Willebrand Factor; AthletesProthrombin timeFactor VIIImedicine.diagnostic_testbiologyChemistryThrombinFibrinogenThrombosisHematologyMiddle Agedprothrombotic factors blood coagulation sportprothrombotic factorsEndocrinologyCoagulationAthletesthrombin generationHemostasishemostasisPhysical Endurancebiology.proteinPartial Thromboplastin TimeCardiology and Cardiovascular Medicinesportcirculatory and respiratory physiology030215 immunologyPartial thromboplastin timemedicine.drug
researchProduct

The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies.

1976

The pharmacodynamics and pharmacokinetics of the optical enantiomers of phenprocoumon were studied in 5 normal subjects and compared to the racemic mixture. Each subject received a single oral dose of 0.6 mg/kg of racemic, S(-), and R(+) phenprocoumon. S(-) phenprocoumon was 1.6 to 2.6 times as a potent as R(+) phenprocoumon when the area under the effect/time curve was used to quantify the total anticoagulant effect per dose. Comparing the plasma concentrations that elicited the same anticoagulant effect, S(-) phenprocoumon was 1.5 to 2.5 times as potent as R(+) phenprocoumon. The anticoagulant activity of the racemic mixture was between that of the enantiomers. There was no distinct diffe…

AdultMalemedicine.drug_classMetabolic Clearance RateIn Vitro TechniquesPhenprocoumonStructure-Activity RelationshipPharmacokineticsCoumarinsmedicineHumansPharmacology (medical)Serum AlbuminPharmacologyVolume of distributionChromatographyChemistryAnticoagulantAnticoagulantsStereoisomerismHuman serum albuminKineticsPharmacodynamicsPhenprocoumonProthrombin TimeRacemic mixtureEnantiomermedicine.drugProtein BindingClinical pharmacology and therapeutics
researchProduct

Role of factor V Leiden or G20210A prothrombin mutation in patients with symptomatic pulmonary embolism and deep vein thrombosis: a meta-analysis of …

2012

AdultMalemedicine.medical_specialtyAdolescentDeep veinRisk AssessmentGastroenterologyYoung AdultRisk FactorsInternal medicineOdds RatiomedicineFactor V LeidenHumansGenetic Predisposition to DiseaseIn patientChildBlood CoagulationAgedAged 80 and overVenous ThrombosisChi-Square DistributionProthrombin mutationbusiness.industryFactor VHematologyOdds ratioMiddle Agedmedicine.diseaseThrombosisSurgeryPulmonary embolismPhenotypemedicine.anatomical_structureMeta-analysisMutationFemaleProthrombinPulmonary Embolismbusiness
researchProduct

Superficial venous thrombosis: Prevalence of common genetic risk factors and their role on spreading to deep veins

2008

Introduction. Superficial venous thrombosis (SVT) has been considered for a long time a limited clinical condition with a low importance, but this approach has changed in recent years, when several studies demonstrated spreading to deep veins occurring from 7.3 to 44%, with high prevalence of pulmonary embolism . Materials and Methods. To evaluate the prevalence of genetic risk factors for VTE in patients suffering from SVT on both normal and varicose vein, and to evaluate their role on spreading to deep veins, we studied 107 consecutive outpatients with symptomatic SVT. Ultrasound examination was performed, and the presence of FV Leiden, Prothrombin G20210A mutation, MTHFR C677T mutation w…

AdultMalemedicine.medical_specialtyAdolescentDeep veinThrombophiliaGastroenterologyVeinsCohort StudiesVaricose VeinsYoung AdultRisk FactorsInternal medicineVaricose veinsmedicinePrevalenceHumansGenetic Predisposition to DiseaseMethylenetetrahydrofolate Reductase (NADPH2)Venous ThrombosisColor-duplex-Ultrasonography Genetic Risk Factors Superficial Venous Thrombosis Venous ThromboembolismVascular diseasebusiness.industryFactor VHematologyMiddle Agedmedicine.diseaseThrombosisSettore MED/11 - Malattie Dell'Apparato CardiovascolarePulmonary embolismVenous thrombosismedicine.anatomical_structureEmbolismMutationFemaleProthrombinRadiologymedicine.symptombusinessPhlebitisPulmonary Embolism
researchProduct